etoposide has been researched along with bortezomib in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (32.65) | 29.6817 |
| 2010's | 29 (59.18) | 24.3611 |
| 2020's | 4 (8.16) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bednarski, PJ; Emmrich, T; Hirt, C; Kiefer, T; Leffler, U; Lemmerhirt, H; Link, A; Schulz, R; Sydow, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| McConkey, DJ; Williams, SA | 1 |
| Ballestrero, A; Belka, C; Boy, D; Brossart, P; Cirmena, G; Dal Bello, G; Nencioni, A; Patrone, F; Wesselborg, S; Wille, L | 1 |
| Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
| Glasmacher, A; von Lilienfeld-Toal, M | 1 |
| Anastasiadis, AG; Argyropoulou, P; Bourikas, G; Kaloutsi, V; Margaritis, D; Pantelidou, D; Prassopoulos, P; Tsatalas, C | 1 |
| Bohlius, J; Engert, A; Hülsewede, H; Kober, T | 1 |
| Arpaci, F; Ataergin, S; Cetin, T; Gunhan, O; Kaya, A; Kaya, T | 1 |
| Akpek, G; Badros, A; Fenton, R; Goloubeva, O; Harris, C; Meisenberg, B; Rapoport, AP; Ruehle, K; Westphal, S | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Mohiuddin, A; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Woods, G; Zangari, M | 1 |
| Chow, L; Eckhardt, SG; Gore, L; Lieu, C; Morrow, M; O'Bryant, CL; Pierson, AS; Tran, ZV; Wright, JJ | 1 |
| Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG | 1 |
| Biron, P; Ghesquières, H; Labidi, SI; Nicolas, EV; Sebban, C | 1 |
| Broggini, M; Carrassa, L; Crippa, F; Damia, G; Ganzinelli, M; Tavecchio, M | 1 |
| Heider, U; Jakob, C; Kaiser, M; Lamottke, B; Mieth, M; Sezer, O; von Metzler, I | 1 |
| Alessandrino, EP; Barbarano, L; Bernasconi, P; Cafro, AM; Carella, AM; Corso, A; Grillo, G; Lazzarino, M; Mangiacavalli, S; Montalbetti, L; Morra, E; Pascutto, C; Spriano, M; Varettoni, M | 1 |
| Mateos, MV; San-Miguel, JF | 1 |
| Brancolini, C; Potu, H; Sgorbissa, A | 1 |
| Chang, I; Chen, Z; Kang, M; Song, J; Wang, CY | 1 |
| He, XX; Huang, JJ; Huang, Y; Li, ZM; Lin, TY; Tian, Y; Xiao, J | 1 |
| Anderlini, P; Fanale, M; Fayad, L; Horowitz, S; Ji, Y; Kwak, LW; Liboon, MJ; Nunez, C; Popat, U; Pro, B; Samaniego, F; Younes, A | 1 |
| Hawley, RG; Hawley, TS; Riz, I; Toma, I; Zweier-Renn, LA | 1 |
| Chang, HC; De La Rosa, M; Han, L; Lupov, IP; Oza, K; Pelloso, D; Robertson, MJ; Sahu, RP; Schwartz, A; Travers, JB; Voiles, L | 1 |
| Andemariam, B; Coleman, M; Elstrom, RL; Furman, RR; Leonard, JP; Martin, P; Ruan, J; Shore, TB | 1 |
| Borst, J; Rooswinkel, RW; van de Kooij, B; Verheij, M | 1 |
| Chen, CI; Chu, CM; Cserti-Gazdewich, C; Jiang, H; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Rabea, A; Reece, DE; Tiedemann, R; Trudel, S; Tsang, R | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM | 1 |
| Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Castillo, JJ; Reagan, JL; Sikov, WM; Winer, ES | 1 |
| Alsina, M; Baz, RC; Fulp, W; Griffin, PT; Ho, VQ; Nishihori, T; Shain, KH | 1 |
| Bhatnagar, B; Blum, W; Canning, R; Devine, SM; Garzon, R; Geyer, S; Klisovic, R; Marcucci, G; Vasu, S; Walker, AR; Walsh, K; Wang, H; Wu, YZ | 1 |
| Austin, CA; Bramley, RL; Cowell, IG; Jackson, GH; Lee, KC | 1 |
| Fedele, PL; Gilbertson, M; Gregory, GP; Grigoriadis, G; Kumar, B; Opat, S; Shortt, J | 1 |
| Abel, H; Ambinder, R; Barta, SK; Baydoun, HH; Caruso, B; Cheng, X; Harding, J; Jacobson, S; Noy, A; Parekh, S; Phillips, A; Ramos, JC; Ratner, L; Rauch, D | 1 |
| Kobayashi, H; Miyagi, N | 1 |
| Arora, N; Gupta, A; Sadeghi, N | 1 |
| Dittus, C; Ellsworth, S; Grover, N; Park, SI; Tan, X | 1 |
| Baldini, F; Bibas, M; Cartron, G; Castillo, JJ; Cwynarski, K; Dierickx, D; Fedele, P; Gilbertson, M; Grigoriadis, G; Guerrero-Garcia, T; Lansigan, F; Linnik, Y; Mogollon, R; Navarro, JT; Ninkovic, S; Olszewski, AJ; Reagan, JL; Tchernonog, E; Tousseyn, T | 1 |
| Aboulafia, D; Ambinder, RF; Cesarman, E; Henry, D; Lee, J; Looney, D; Maldarelli, F; Mitsuyasu, R; Noy, A; Ramos, JC; Reid, EG; Sparano, J; Wachsman, W; Yahyaei, S | 1 |
| Barlogie, B; Mouhieddine, TH; Teruya-Feldstein, J | 1 |
| Böhmer, LH; Chitu, DA; de Jong, D; de Jongh, E; de Weerdt, O; Doorduijn, JK; Hoogendoorn, M; Kersten, MJ; Kibbelaar, RE; Kluin-Nelemans, HC; Leys, RBL; Lugtenburg, PJ; MacKenzie, MA; Minnema, MC; Snijders, TJF; van Gelder, M; van Marwijk Kooij, R; Van't Veer, MB; Zijlstra, JM | 1 |
| Anderson, KC; Badros, A; Beksac, M; Bladé, J; Caers, J; Cavo, M; Dimopoulos, MA; Dispenzieri, A; Einsele, H; Engelhardt, M; Fernández de Larrea, C; Gahrton, G; Gay, F; Hájek, R; Hungria, V; Jurczyszyn, A; Kröger, N; Kyle, RA; Leal da Costa, F; Leleu, X; Lentzsch, S; Mateos, MV; Merlini, G; Mohty, M; Moreau, P; Rasche, L; Reece, D; Richardson, PG; Rosiñol, L; Sezer, O; Sonneveld, P; Usmani, SZ; Van de Donk, NWCJ; Vanderkerken, K; Vesole, DH; Waage, A; Zamagni, E; Zweegman, S | 1 |
| Andoh, S; Hagiwara, S; Hirai, R; Itoi, S; Komuro, M; Mitsui, Y; Miwa, A; Nakamura, M; Sekine, R; Takeshita, M; Tanimura, A; Togano, T | 1 |
5 review(s) available for etoposide and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The current status of thalidomide in the management of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Tumor Necrosis Factor-alpha | 2005 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine | 2006 |
How to treat a newly diagnosed young patient with multiple myeloma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning | 2009 |
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Disease Management; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasmacytoma; Prognosis; Transplantation, Autologous | 2021 |
12 trial(s) available for etoposide and bortezomib
| Article | Year |
|---|---|
Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2006 |
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Bone Marrow; Boronic Acids; Bortezomib; Cisplatin; Creatinine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2007 |
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Thrombocytopenia | 2009 |
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Constipation; Cyclophosphamide; Dexamethasone; Dizziness; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Constipation; Cyclophosphamide; Dexamethasone; Diarrhea; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2010 |
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Pyrazines; Recurrence; Treatment Outcome; Young Adult | 2011 |
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Rituximab; Time Factors; Treatment Outcome | 2012 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous | 2014 |
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Rabbits; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Plasmablastic Lymphoma; Prednisone; Retrospective Studies; Survival Rate; Vincristine | 2019 |
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; APOBEC-3G Deaminase; Bortezomib; Carboplatin; Etoposide; Female; HIV; HIV Infections; Humans; Ifosfamide; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Oncolytic Virotherapy; Recurrence; Rituximab; Viral Load | 2018 |
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Netherlands; Prednisone; Progression-Free Survival; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Failure; Vincristine; Young Adult | 2020 |
32 other study(ies) available for etoposide and bortezomib
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of a glutathione peroxidase inhibitor that reverses resistance to anticancer drugs in human B-cell lymphoma cell lines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Catalytic Domain; Cattle; Cell Line, Tumor; Crystallography, X-Ray; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glutathione Peroxidase; Humans; Hydrazones; Inhibitory Concentration 50; Lymphoma, B-Cell; Molecular Structure | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA, Neoplasm; Etoposide; Humans; Male; Nuclear Proteins; Oncogene Proteins, Viral; Papillomaviridae; Peptide Hydrolases; Phosphorylation; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Subcellular Fractions; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53 | 2003 |
Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line; Cell Survival; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Flow Cytometry; Humans; Immunoblotting; Jurkat Cells; Leupeptins; Membrane Glycoproteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; NF-kappa B; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
Successful treatment of lymph node extramedullary plasmacytoma with bortezomib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Doxorubicin; Etoposide; Humans; Injections, Intravenous; Lymph Nodes; Male; Middle Aged; Peritoneal Neoplasms; Plasmacytoma; Pyrazines; Radiotherapy Dosage; Stem Cell Transplantation; Tomography, X-Ray Computed; Transplantation, Autologous | 2006 |
VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Etoposide; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Protease Inhibitors; Pyrazines; Remission Induction | 2006 |
Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Hepatic Veno-Occlusive Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Down-Regulation; Doxorubicin; Etoposide; Female; Fluorescent Antibody Technique; Fluorouracil; Genes, p53; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Protein Kinases; Pyrazines; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays | 2008 |
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Drug Synergism; Etoposide; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Topoisomerase II Inhibitors | 2009 |
Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carbon-Nitrogen Lyases; Cell Line, Tumor; Down-Regulation; Endopeptidases; Etoposide; Gene Silencing; Humans; Interferon alpha-2; Interferon-alpha; Protease Inhibitors; Pyrazines; Recombinant Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Ubiquitin Thiolesterase | 2010 |
Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; beta Catenin; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Etoposide; Flow Cytometry; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Pyrazines; Signal Transduction; Stem Cells; Wnt Proteins | 2010 |
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Everolimus; Humans; Jurkat Cells; Lymphoma, T-Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazines; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Vincristine | 2012 |
Apoptotic role of IKK in T-ALL therapeutic response.
Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-myc; Pyrazines; Receptor, Notch1; Signal Transduction; Vincristine | 2011 |
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Carmustine; Cells, Cultured; Drug Interactions; Etoposide; Flow Cytometry; Gene Expression; Humans; Interleukin-12; Interleukin-2; Leukocytes, Mononuclear; Lymphoma; Melanoma; Mice; Mice, Inbred C57BL; Protein Biosynthesis; Pyrazines; RNA Stability; Skin Neoplasms; STAT4 Transcription Factor; Ubiquitin | 2011 |
Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; T-Lymphocytes; Tumor Suppressor Protein p53 | 2012 |
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Injections, Spinal; Kaplan-Meier Estimate; Lenalidomide; Male; Meninges; Middle Aged; Multiple Myeloma; Orbit; Proportional Hazards Models; Pyrazines; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Spine; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Treatment Outcome; Vincristine | 2015 |
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cytarabine; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Staurosporine; Treatment Outcome; Young Adult | 2016 |
Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
Topics: Antigens, Neoplasm; Bortezomib; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Leupeptins; Mitoxantrone; Poly-ADP-Ribose Binding Proteins; Proteasome Inhibitors; Topoisomerase II Inhibitors | 2016 |
Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Infusions, Subcutaneous; Male; Plasmablastic Lymphoma; Prednisone; Treatment Outcome; Vincristine | 2016 |
Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Prednisone; Raltegravir Potassium; Treatment Outcome; Vincristine | 2016 |
HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Female; HIV Infections; Humans; Middle Aged; Plasmablastic Lymphoma; Prednisone; Remission Induction; Vincristine | 2017 |
Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Induction Chemotherapy; Male; Plasmablastic Lymphoma; Prednisone; Vincristine | 2017 |
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
Topics: Adult; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Plasmablastic Lymphoma; Prednisone; Retrospective Studies; Time Factors; Treatment Outcome; Vincristine | 2018 |
Hemophagocytic relapsed intramedullary plasmacytoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bortezomib; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Magnetic Resonance Imaging; Melphalan; Neoplasm Recurrence, Local; Oligopeptides; Plasmacytoma; Positron Emission Tomography Computed Tomography; Pubic Bone; Rare Diseases; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2020 |
Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2022 |